Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

被引：43

作者：

Gerecitano, John ^{[1
]}

Portlock, Carol ^{[1
]}

Moskowitz, Craig ^{[1
]}

Hamlin, Paul ^{[1
]}

Straus, David ^{[1
]}

Zelenetz, Andrew D. ^{[1
]}

Zhang, Zhigang ^{[2
]}

Dumitrescu, Otilia ^{[3
]}

Sarasohn, Debra ^{[3
]}

Lin, Dorothy ^{[1
]}

Pappanicholaou, Jennifer ^{[1
]}

Cortelli, Barbara M. ^{[4
]}

Neylon, Ellen ^{[4
]}

Hamelers, Rachel ^{[4
]}

Wright, John ^{[5
]}

O'Connor, Owen A. ^{[4
,6
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA

[4] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA

[5] Natl Canc Inst, Drug Dev Branch, CTEP, Washington Dc, WA USA

[6] Columbia Univ, Coll Phys & Surg, New York Presbyterian Hosp, Med Ctr, New York, NY USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2009年 / 146卷 / 06期

关键词：

bortezomib; follicular lymphoma; mantle cell lymphoma; non-Hodgkin lymphoma; proteasome inhibitor; PROTEASOME INHIBITOR BORTEZOMIB; NON-HODGKINS-LYMPHOMA; IN-VITRO; CANCER; TRIAL;

D O I：

10.1111/j.1365-2141.2009.07775.x

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

P>Twice-weekly bortezomib has proven activity in mantle cell (MCL) and indolent lymphomas. This study explored a weekly schedule of bortezomib in follicular lymphoma (FL) and MCL. Although weekly bortezomib was better tolerated, the overall response rate (ORR) was inferior (18% vs. 50%, P = 0 center dot 02) with no complete remissions (CR) (compared with 18% CR for the twice-weekly schedule). Progression-free survival (PFS) was not different. The weekly schedule of bortezomib was less toxic, but yielded fewer and lower quality responses than twice-weekly bortezomib. Given the similar PFS, the weekly schedule may still be appropriate for some patients.

引用

页码：652 / 655

页数：4

共 15 条

[1]

A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150 [J].

Belch, A. ;

Kouroukis, C. T. ;

Crump, M. ;

Sehn, L. ;

Gascoyne, R. D. ;

Klasa, R. ;

Powers, J. ;

Wright, J. ;

Eisenhauer, E. A. .

ANNALS OF ONCOLOGY, 2007, 18 (01) :116-121

[2]

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

[3]

de Vos S, 2005, BLOOD, V106, p10A

[4]

DEVOS S, 2004, P AM ASSOC CANC RES, V45, P546

[5]

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma [J].

Fisher, Richard I. ;

Bernstein, Steven H. ;

Kahl, Brad S. ;

Djulbegovic, Benjamin ;

Robertson, Michael J. ;

de Vos, Sven ;

Epner, Elliot ;

Krishnan, Amrita ;

Leonard, John P. ;

Lonial, Sagar ;

Stadtmauer, Edward A. ;

O'Connor, Owen A. ;

Shi, Hongliang ;

Boral, Anthony L. ;

Goy, Andre .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) :4867-4874

[6]

A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed/refractory indolent and mantle cell lymphomas [J].

Gerecitano, J. F. ;

Portlock, C. ;

Hamlin, P. ;

Moskowitz, C. ;

Noy, A. ;

Straus, D. J. ;

Zelenetz, A. D. ;

Schulman, P. ;

Dumitrescu, O. ;

O'Connor, O. A. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[7]

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma [J].

Goy, A ;

Younes, A ;

McLaughlin, P ;

Pro, B ;

Romaguera, JE ;

Hagemeister, F ;

Fayad, L ;

Dang, NH ;

Samaniego, F ;

Wang, M ;

Broglio, K ;

Samuels, B ;

Gilles, F ;

Sarris, AH ;

Hart, S ;

Trehu, E ;

Schenkein, D ;

Cabanillas, F ;

Rodriguez, AM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :667-675

[8]

Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma - A phase 2 trial of the Minnie Pearl Cancer Research Network [J].

Hainsworth, John D. ;

Spigel, David R. ;

Barton, John ;

Farley, Cindy ;

Schreeder, Marshall ;

Hon, Jeremy ;

Greco, F. Anthony .

CANCER, 2008, 113 (04) :765-771

[9]

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma [J].

Heider, Ulrike ;

von Metzler, Ivana ;

Kaiser, Martin ;

Rosche, Marleen ;

Sterz, Jan ;

Roetzer, Susanne ;

Rademacher, Jessica ;

Jakob, Christian ;

Fleissner, Claudia ;

Kuckelkorn, Ulrike ;

Kloetzel, Peter-Michael ;

Sezer, Orhan .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 80 (02) :133-142

[10]

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma [J].

O'Connor, OA ;

Wright, J ;

Moskowitz, C ;

Muzzy, J ;

MacGregor-Cortelli, B ;

Stubblefield, M ;

Straus, D ;

Portlock, C ;

Hamlin, P ;

Choi, E ;

Dumetrescu, O ;

Esseltine, D ;

Trehu, E ;

Adams, J ;

Schenkein, D ;

Zelenetz, AD .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :676-684

← 1 2 →